Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocugen (OCGN) Cash & Equivalents (2016 - 2024)

Ocugen's Cash & Equivalents history spans 11 years, with the latest figure at $15.7 million for Q2 2024.

  • For Q2 2024, Cash & Equivalents fell 77.76% year-over-year to $15.7 million; the TTM value through Jun 2024 reached $15.7 million, down 77.76%, while the annual FY2023 figure was $39.5 million, 49.12% down from the prior year.
  • Cash & Equivalents reached $15.7 million in Q2 2024 per OCGN's latest filing, down from $26.4 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $129.8 million in Q1 2022 to a low of $3.2 million in Q1 2020.
  • Average Cash & Equivalents over 5 years is $62.3 million, with a median of $60.9 million recorded in 2023.
  • Peak YoY movement for Cash & Equivalents: skyrocketed 2106.07% in 2020, then crashed 77.76% in 2024.
  • A 5-year view of Cash & Equivalents shows it stood at $24.0 million in 2020, then surged by 295.02% to $95.0 million in 2021, then dropped by 18.32% to $77.6 million in 2022, then plummeted by 49.12% to $39.5 million in 2023, then tumbled by 60.22% to $15.7 million in 2024.
  • Per Business Quant, the three most recent readings for OCGN's Cash & Equivalents are $15.7 million (Q2 2024), $26.4 million (Q1 2024), and $39.5 million (Q4 2023).